Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
TAIPEI, July 28, 2026 /PRNewswire/ -- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial evaluating YA-101, its flagship candidate for...
Torrey Pines Medicine Secures Angel Round to Advance Next-Generation Ultra-Long-Acting Peptide Therapeutics
Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's proprietary PepTetris™ peptide discovery platform for obesity, diabetes, and other metabolic diseases Developing a differentiated portfolio of ultra-long-acting peptide therapeutics targeting metabolic diseases, including obesity, type...
Smartee Hosts Academic Programs in Thailand Highlighting Mandibular Repositioning Technology
BANGKOK, July 28, 2026 /PRNewswire/ -- Smartee Denti-Technology recently participated in two academic events in Bangkok, Thailand, focusing on the clinical principles and applications of its Mandibular Repositioning Technology. The programs brought together orthodontic professionals to exchange perspectives on the diagnosis and management of complex skeletal Class II malocclusions. On July 14, Smartee hosted the Thailand...
New report identifies opportunities to help more patients in Asia Pacific benefit from advances in AFib care
Growing physician confidence in pulsed field ablation highlights the need to strengthen referral pathways, education and healthcare system readiness SINGAPORE, July 28, 2026 /PRNewswire/ -- Boston Scientific today revealed findings from a new report showing that, while physicians in Asia Pacific (APAC) increasingly view pulsed field ablation (PFA) as the...
The costly winter pet mistakes Australians are making
MELBOURNE, Australia, July 28, 2026 /PRNewswire/ -- As cost-of-living pressures bite, Petstock is warning pet parents not to overlook subtle winter health changes, which can lead to vet bills of up to $15,600 if left untreated. Dog snuggled up with Buddy toy next to fireplace in winter Australians spend more than $1.9 billion on veterinary...
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences. Morgan Stanley Biotech Without Borders SeriesDate: Tuesday, July 28, 2026Time: US: 10:00am...
TriNetX Appoints August Calhoun Chief Executive Officer
Jeff Margolis Resumes Chairman Role as Company Completes CEO Transition CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- TriNetX, The Global Truth Engine for Better Human Health™ and operator of the world's leading federated health data network, today announced the appointment of August Calhoun as Chief Executive Officer, effective immediately. Jeff Margolis,...
HoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics
Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies Targets the rapidly growing global sleep clinical research market with advanced biomarker analytics and continual learning technology Leverages experience from clinical studies involving more than 10,000 participants to support global multicenter trials BOSTON, July 27, 2026 /PRNewswire/ -- HoneyNaps, today announced...
AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem
SHANGHAI, July 27, 2026 /PRNewswire/ -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced that construction of its new R&D building has officially broken ground at the Shanghai Fengxian site. The project marks a pivotal infrastructure step in strengthening AsymBio's...
Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information Seegene to validate the clinical utility of comprehensive HPV &...
